From the Cerebrovascular Clinical Research Center and the Department of Neurologic Surgery, Mayo Clinic and
Mayo Foundation, Rochester, Minnesota were used in 183 or approximately one-third of these cases. Surgical and anesthetic techniques have been reported previously. 10,13 All patients were anticoagulated intraoperatively with 5,000 to 10,000 U of heparin administered intravenously just before carotid clamping. Each shunt was used only once. Approximately 270 of these procedures were done from January 1970 to October 1973, during which time we routinely found thrombus deposition within the lumen of the shunt after removal, particularly at the proximal and distal orifices. On several occasions we documented thrombotic occlusion of the shunt with resultant acute deterioration of the EEG pattern and reduction of CBF, as measured by intra-arterial injections of xenon-133. One patient with a shunt in place suffered a permanent neurologic deficit from emboli, possibly arising from thrombus accumulating within the shunt itself. The following case report is illustrative.
Case Report
A 71-year-old man with multiple, recent, right middle cerebral artery transient ischemic attacks and angiographic evidence of a highgrade stenotic and ulcerated plaque in the right cervical internal carotid artery underwent right carotid endarterectomy. Intraoperative baseline CBF was 35 ml/100 g of cerebral tissue and the EEG tracing was normal. After intravenous administration of 7,000 U of heparin, the right common, internal, and external carotid arteries were occluded to isolate the lesion, at which time there was a prompt, marked deterioration of the EEG pattern with severe reduction of the amplitude and slowing over the right hemisphere. CBF at this time An occluding thrombus in an untreated shunt from a dog without anticoagulation formed a cast of the lumen of the shunt (Fig. 2) . Interestingly, a white thrombus typically formed at the point where the shunt begins to narrow (area B in Fig. 2 ). Proximal to this and filling the larger diameter of the shunt (area A) was found a red thrombus assumed to be a propagated clot, and distally in the narrower portion of the shunt (area C) was a mixed red and white thrombus.
Scanning electron microscope examination of a cast showed it to be composed of a fibrin meshwork, platelets, and red blood cells. As suggested by gross examination, there was a difference in the makeup of the thrombus at the site of shunt narrowing, the platelets predominating in this region compared with the proximal and distal areas of the thrombus where there were fewer platelets but relatively increased fibrin and trapped red cells (Fig. 3 ). Discussion Impregnation of polymer surfaces with the TDMACheparin complex effectively retards surface-induced thrombosis7 and has been used successfully in permanent intravascular prostheses8 and temporary shunts.1"5
In our clinical experience with carotid endarterectomy shunts, the preexistent problem of shunt thrombosis has been virtually eliminated by the routine use of heparin-impregnated Silastic shunts.
Comparative studies using both untreated and heparinimpregnated shunts in dogs confirmed a high degree of thromboresistance in the heparin-impregnated shunts and virtually no thrombogenicity when used with systemic heparin anticoagulation. During carotid endarterectomy, we routinely give heparin intravenously just before vessel clamping; this provides additional protection if a shunt is required and protects the occluded vessels if a shunt is not required. In approximately two-thirds of our patients, a shunt is not required; we believe a shunt should not be used unless indicated."
The shunts we use have been designed to be placed in the common and internal carotid arteries with minimal trauma to the arterial wall. Such a design with distal narrowing of the lumen undoubtedly produces some turbulent flow-which is known to enhance thrombus formation9 and may explain our finding of solid platelet thrombus at the site of narrowing 'of the untreated shunts in dogs without anticoagulation: We found no predilection for thrombus accumulation at this site in the heparin-impregnated shunts.
Although we routinely use a shunt only once clinically, heparin-impregnated shunts have been reused many times in animals (up to 5 hours of exposure) without apparent loss of thromboresistance. Prolonged exposure of the heparinized surface to high blood flow results in some elution of the bonded heparin,67 though nonthrombogenicity has been shown to be retained despite large heparin loss on other heparincoated surfaces.3 Although adsorption of thrombin to certain heparinized surfaces has been documented and may reduce the surface thromboresistance,2 it has not been shown to be a factor in intra-arterial Silastic shunts impregnated with a TDMAC-heparin complex.
Addendum
Since this manuscript was submitted for publication, Battelle Laboratories has discontinued their service of heparinizing our shunts and we now carry out this relatively simple process in our laboratories.
